Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. (AKTS) is a healthcare company (biotechnology) based in the United States. The share price is $16.13, down 0.19% on the day, which values the company at $900.02M. Price as of 17 Nov 2026, 17:37 UTC, from Yahoo Finance.
Key facts
- Share price
- $16.13−0.19% today
- Market value
- $900.02M
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Aktis Oncology, Inc. in more detail
AKTS trades at -7.1× next year's expected earnings, 72.7× sales.
Over the last five fiscal years Aktis Oncology, Inc. has compounded revenue 29.4% a year.
In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.
2 of the superinvestors tracked here hold AKTS, including Peter Kolchinsky (0.4% of the portfolio), Julian and Felix Baker (0.2% of the portfolio).
Superinvestors holding AKTS
2 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management0.37% of portfolio · $42.4M · trimmed · Q2 2026
- Julian and Felix Baker Baker Bros. Advisors0.16% of portfolio · $32.1M · Q2 2026
Aktis Oncology, Inc. (AKTS): questions and answers
What is Aktis Oncology, Inc.'s market cap?
Aktis Oncology, Inc. is valued at $900.02M at a share price of $16.13.
How fast is Aktis Oncology, Inc. growing?
Over the last five fiscal years Aktis Oncology, Inc.'s revenue grew 29.4% a year.
Does AKTS pay a dividend?
Aktis Oncology, Inc. does not currently pay a regular dividend.
Which famous investors own AKTS?
In their latest quarterly filings, Peter Kolchinsky (0.4% of the portfolio), Julian and Felix Baker (0.2% of the portfolio) hold AKTS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Aktis Oncology, Inc. (AKTS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/AKTS
Underlying data: Yahoo Finance; company filings with the SEC.